• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Biogen Idec

Biogen Idec

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Biogen Idec Presents Positive Interim Results from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at 2015 AD/PD™ Conference

    Biogen Idec Presents Positive Interim Results from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at 2015 AD/PD™ Conference

  2. UPDATE: Tenet climbs on deal; Carnival, Biogen dip on downgrades

    UPDATE: Tenet climbs on deal; Carnival, Biogen dip on downgrades

  3. Research and Markets: Top 50 Big Biotech Partnering and M&A Deal Trends Report 2015

    Research and Markets: Top 50 Big Biotech Partnering and M&A Deal Trends Report 2015

  4. S&P 500's slow-motion breakout attempt remains -2-

    S&P 500's slow-motion breakout attempt remains -2-

  5. UPDATE: S&P 500's slow-motion breakout attempt -2-

    UPDATE: S&P 500's slow-motion breakout attempt -2-

  6. Suspect in Body-Parts Discovery to Appear in Court Monday -- Update

    Suspect in Body-Parts Discovery to Appear in Court Monday -- Update

  7. Street gushes over Alzheimer's drug, but some worry about overreaction

    Street gushes over Alzheimer's drug, but some worry about overreaction

  8. Biogen's stock falls on first day with new name after analyst downgrade

    Biogen's stock falls on first day with new name after analyst downgrade

  9. UPDATE: Nike jumps on earnings; Tiffany struggles with dollar headwinds

    UPDATE: Nike jumps on earnings; Tiffany struggles with dollar headwinds

  10. UPDATE: Chesapeake shares rise after capex budget trimmed

    UPDATE: Chesapeake shares rise after capex budget trimmed

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.